Hepatitis B Annual
Home

Current Issue  

Back Issues   

Instructions   

Search Login    Users online: 81 Print this page  Email this page Small font sizeDefault font sizeIncrease font size 
>>> Ahead of Print <<<
REVIEW ARTICLE
Year : 2011  |  Volume : 8  |  Issue : 1  |  Page : 71-83

Interferon for HBV infection: Plain or Pegylated? Alone or in combination? Concurrent or sequential?


1 Professor and Head, Department of Gastroenterology, DMC and Hospital, Ludhaina, Punjab, India
2 Department of Medicine, DMC and Hospital, Ludhaina, Punjab, India

Correspondence Address:
Ajit Sood
6-E, Tagore Nagar, Ludhiana 141 001, Punjab
India
Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.4103/0972-9747.190081

Rights and Permissions

Hepatitis B Virus (HBV) infection is a significant global public health problem. Treatment options that have evolved rapidly over the last two decades have proven to be effective, but clear recommendations regarding the choice of first-line therapy are lacking. With the emergence of pegylated interferon (PEG IFN), conventional interferon has been relegated into the background and has a very limited role in the treatment of chronic Hepatitis B. Pegylated interferon α2a / 2b treatment has been documented to successfully achieve normalization of alanine aminotransferase (ALT) and viral suppression in nearly half of the patients. However, HBsAg loss can be achieved only rarely. Combination therapy, comprising of pegylated interferon plus nucleos(t)ide analogs theoretically appear attractive because of the synergistic anti-viral and immunomodulatory actions, but the available present literature does not provide sufficient evidence to recommend the combination therapy. Patient selection is important for tailoring the therapy for patients with chronic hepatitis B. Pegylated interferon seems suitable for young patients with raised ALTs, moderately high viral load, and having Genotype A / B; the advantage being finite duration of therapy and no risk of emergence of drug resistance.


[FULL TEXT] [PDF]*
Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)
 

 Article Access Statistics
    Viewed2048    
    Printed178    
    Emailed0    
    PDF Downloaded52    
    Comments [Add]    

Recommend this journal